ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-28 15:36 |
Franchissement de seuil et déclaration d'intention
|
French | 135.9 KB | ||
| 2025-11-19 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 21.0 KB | ||
| 2025-11-03 22:05 |
Abivax annonce les resultats rapportes par les patients issus des essais d'indu…
|
French | 35.6 KB | ||
| 2025-10-24 09:36 |
Franchissement de seuils
|
French | 126.8 KB | ||
| 2025-10-15 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.8 KB | ||
| 2025-10-09 15:53 |
Franchissement de seuil
|
French | 115.1 KB | ||
| 2025-10-06 10:00 |
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Re…
|
English | 15.0 KB | ||
| 2025-10-05 17:00 |
Abivax annonce la presentation des derniers resultats de l'essai ABTECT de 8 se…
|
French | 28.9 KB | ||
| 2025-10-03 11:54 |
Franchissement de seuil
|
French | 119.6 KB | ||
| 2025-09-29 22:05 |
Abivax annonce lacceptation dun late-breaking abstract supplementaire sur les…
|
French | 33.6 KB | ||
| 2025-09-23 22:05 |
Abivax annonce la presentation des dernieres donnees sur obefazimod issues des …
|
French | 34.3 KB | ||
| 2025-09-16 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | ||
| 2025-09-16 09:59 |
Franchissement de seuil
|
French | 121.4 KB | ||
| 2025-09-12 17:45 |
Abivax intègrera les indices CAC Mid 60 et SBF 120 suite à la révision annuelle…
|
French | 160.0 KB | ||
| 2025-09-12 17:45 |
Abivax integrera les indices CAC Mid 60 et SBF 120 suite a la revision annuelle…
|
French | 21.0 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
